Tyra Biosciences (NASDAQ:TYRA) Announces Earnings Results

Tyra Biosciences (NASDAQ:TYRA) released its earnings results on Thursday. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.05, Zacks reports.

Tyra Biosciences Stock Up 2.5 %

Shares of TYRA stock traded up $0.25 on Friday, hitting $9.91. The stock had a trading volume of 45,611 shares, compared to its average volume of 229,238. Tyra Biosciences has a one year low of $9.49 and a one year high of $29.60. The business has a 50 day moving average price of $12.59 and a 200 day moving average price of $16.45. The company has a market cap of $501.22 million, a PE ratio of -6.15 and a beta of 1.09.

Insiders Place Their Bets

In other news, Director Nina S. Kjellson sold 5,401 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the sale, the director now owns 443,885 shares in the company, valued at approximately $6,107,857.60. The trade was a 1.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 21,998 shares of company stock worth $344,818 in the last three months. Corporate insiders own 15.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TYRA. UBS Group began coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Tyra Biosciences currently has an average rating of “Buy” and a consensus price target of $30.50.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.